RT Journal Article
T1 Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry.
A1 Formiga, Francesc
A1 Rubio-Rivas, Manuel
A1 Mora-Lujan, Jose Maria
A1 Escudero, Samara Campos
A1 Fernandez-Madera-Martinez, Rosa
A1 Mendez-Bailon, Manuel
A1 Duran-Del-Campo, Pedro
A1 Riaño-Perez, Andrea
A1 Garcia-Sanchez, Francisco-Javier
A1 Alcala-Pedrajas, Jose Nicolas
A1 Arnedo-Hernandez, Sergio
A1 Hernandez-Milian, Almudena
A1 Latorre-Diez, Ana
A1 Gil-Sanchez, Ricardo
A1 Boixeda, Ramon
A1 Vicente, Julio
A1 Cortes, Begoña
A1 Perez, Carmen Mella
A1 Guisado-Espartero, Maria Esther
A1 Castro, Jose Lopez
A1 Rodriguez-Suarez, Santiago
A1 Varona, Jose F
A1 Gomez-Huelgas, Ricardo
A1 Ramos-Rincon, Jose Manuel
K1 Acetylsalicylic acid
K1 COVID-19
K1 Coronavirus
K1 Mortality
K1 Área Sanitaria Norte de Córdoba
K1 Area de Gestión Sanitaria Sur de Córdoba
AB Acetylsalicylic acid (ASA) is widely used in the treatment and prevention of cardiovascular disorders. Our objective is to evaluate its possible protective role, not only in mortality but also in other aspects such as inflammation, symptomatic thrombosis, and intensive care unit (ICU) admission in hospitalized COVID-19 patients. We realized an observational retrospective cohort study of 20,641 patients with COVID-19 pneumonia collected and followed-up from Mar 1st, 2020 to May 1st, 2021, from the nationwide Spanish SEMI-COVID-19 Registry. Propensity score matching (PSM) was performed to determine whether treatment with ASA affected outcomes in COVID-19 patients. On hospital admission, 3291 (15.9%) patients were receiving ASA. After PSM, 3291 patients exposed to ASA and 2885 not-exposed patients were analyzed. In-hospital mortality was higher in the ASA group (30.4 vs. 16.9%, p < 0.001) in the global sample. After PSM, no differences were found between groups (30.4 vs. 30.3%, p = 0.938). There were no differences in inflammation, symptomatic thrombosis, or ICU admission. In conclusion, ASA intake is not associated with in-hospital mortality or any other health outcome evaluated after applying PSM analysis in a real-world large sample of hospitalized COVID-19 patients.
PB Springer
YR 2021
FD 2021-11-29
LK http://hdl.handle.net/10668/20886
UL http://hdl.handle.net/10668/20886
LA en
NO Formiga F, Rubio-Rivas M, Mora-Luján JM, Escudero SC, Martinez RFM, Mendez-Bailón M, et al. Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry. Intern Emerg Med. 2022 Apr;17(3):761-775
DS RISalud
RD Apr 14, 2025